Radiation boost after osimertinib for EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding a precise, high-dose type of radiation (called SBRT or SRS) to the targeted therapy pill osimertinib can better control lung cancer that has an EGFR mutation. If you have had a good response to osimertinib but still have a few remaining tumors, this combination may help improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have lung cancer with an EGFR mutation (exon 19 deletion, L858R, or G719X) that has spread to other parts of the body.
- You have been taking osimertinib (Tagrisso) for at least 12 weeks, and your cancer has shrunk but some tumors remain (a partial response).
- You have up to 5 remaining tumor spots in no more than 2 organs, and all of them can be safely treated with a precise, high-dose type of radiation called SBRT (or SRS for brain lesions).
- Your remaining tumors are not suitable for surgery.
- You will need to pause osimertinib for 48 hours before and after each radiation treatment (or up to 5 days for central lung tumors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
This trial tests whether directly treating the remaining lung tumor with surgery or radiation, after initial chemo and osimertinib, can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests combining a targeted pill (EGFR-TKI) with an antibody drug (bevacizumab) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination works better than the pill alone as a first treatment.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
Hear when a new EGF-R Positive Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.